Abnormalities in Inflammatory Cytokines Confer Susceptible to Chronic Neuropathic Pain-related Anhedonia in a Rat Model of Spared Nerve Injury
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Patients with chronic neuropathic pain (CNP) have a higher incidence to develop depression. However, its pathogenesis has not yet been fully elucidated. Here we aimed to investigate the role of inflammatory cytokines in CNP-related anhedonia, which is a core symptom of depression, and to explore the effects of ketamine and parecoxib on pain and anhedonia. Methods: A rat model of spared nerve injury (SNI) was constructed to mimic CNP. Hierarchical cluster analysis of sucrose preference test (SPT) was applied to classify the SNI rats into anhedonia susceptible and unsusceptible. Inflammatory cytokines in medial prefrontal cortex (mPFC) of brain, serum and L2-5 spinal cord were measured. Moreover, effects of ketamine or parecoxib on mechanical withdrawal test (MWT) and SPT in anhedonia susceptible rats were detected. Results: Tumor necrosis factor (TNF)- was increased in mPFC, serum and and spinal cord of anhedonia susceptible rats. Furthermore, anhedonia susceptible and unsusceptible rats both increased the interleukin (IL)-1 level in mPFC, serum and spinal cord. IL-6 was altered in serum and spinal cord, but not in mPFC. IL-10 was significantly altered in mPFC and serum, but not in spinal cord. Additionally, ketamine treatment significantly attenuated the decreased results of MWT and SPT in anhedonia susceptible rats, and that parecoxib significantly improved the MWT score, but failed to alter the result of SPT. Conclusion: These findings suggest that abnormalities in inflammatory cytokines confer susceptible to anhedonia in a rat model of SNI. Ketamine, a fast-acting antidepressant, has pharmacological benefits to alleviate pain and anhedonia symptoms.
Abstract
Objective: Patients with chronic neuropathic pain (CNP) have a higher incidence to develop depression. However, its pathogenesis has not yet been fully elucidated. Here we aimed to investigate the role of inflammatory cytokines in CNP-related anhedonia, which is a core symptom of depression, and to explore the effects of ketamine and parecoxib on pain and anhedonia. Methods: A rat model of spared nerve injury (SNI) was constructed to mimic CNP. Hierarchical cluster analysis of sucrose preference test (SPT) was applied to classify the SNI rats into anhedonia susceptible and unsusceptible. Inflammatory cytokines in medial prefrontal cortex (mPFC) of brain, serum and L2-5 spinal cord were measured. Moreover, effects of ketamine or parecoxib on mechanical withdrawal test (MWT) and SPT in anhedonia susceptible rats were detected. Results: Tumor necrosis factor (TNF)- was increased in mPFC, serum and and spinal cord of anhedonia susceptible rats. Furthermore, anhedonia susceptible and unsusceptible rats both increased the interleukin (IL)-1 level in mPFC, serum and spinal cord. IL-6 was altered in serum and spinal cord, but not in mPFC. IL-10 was significantly altered in mPFC and serum, but not in spinal cord. Additionally, ketamine treatment significantly attenuated the decreased results of MWT and SPT in anhedonia susceptible rats, and that parecoxib significantly improved the MWT score, but failed to alter the result of SPT. Conclusion: These findings suggest that abnormalities in inflammatory cytokines confer susceptible to anhedonia in a rat model of SNI. Ketamine, a fast-acting antidepressant, has pharmacological benefits to alleviate pain and anhedonia symptoms.
참고문헌 (62)
- Gerrits MM, "Longitudinal association between pain, and depression and anxiety over four years", J Psychosom Res, 78, pp.64~70 (2015)
- Goesling J, "Pain and depression : an integrative review of neurobiological and psychological factors", Curr Psychiatry Rep, 15, pp.421~ (2013)
- Bair MJ, "Depression and pain comorbidity : a literature review", Arch Intern Med, 163, pp.2433~2445 (2003)
- de Leon-Casasola OA, "Opioids for chronic pain: new evidence, new strategies, safe prescribing", Am J Med, 126(3 Suppl 1), pp.S3~S11 (2013)
- Nalamachu S, "An overview of pain management: the clinical efficacy and value of treatment", Am J Manag Care, 19(14 Suppl), pp.s261~s266 (2013)
- Finnerup NB, "Pharmacotherapy for neuropathic pain in adults : a systematic review and meta-analysis", Lancet Neurol, 14, pp.162~173 (2015)
- Dworkin RH, "Recommendations for the pharmacological management of neuropathic pain: an overview and literature update", Mayo Clin Proc, 85(3 Suppl), pp.S3~S14 (2010)
- Gilmartin JF, "Depressive symptoms are associated with analgesic use in people with Alzheimer’s disease : Kuopio ALSOVA study", PLoS One, 10, pp.e0117926~ (2015)
- Mohr P, "Management of depression in the presence of pain symptoms", Psychiatr Danub, 22, pp.4~13 (2010)
- Winer ES, "Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample", Psychiatry Res, 218, pp.124~128 (2014)
- Rizvi SJ, "Development and validation of the Dimensional Anhedonia Rating Scale(DARS)in a community sample and individuals with major depression", Psychiatry Res, 229, pp.109~119 (2015)
- Der-Avakian A, "The neurobiology of anhedonia and other reward-related deficits", Trends Neurosci, 35, pp.68~77 (2012)
- Page GG, "Sex differences in sleep, anhedonia, and HPA axis activity in a rat model of chronic social defeat", Neurobiol Stress, 3, pp.105~113 (2016)
- Yamamoto H, "Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT2C receptor dysfunction, and anhedonia in mice", Neuropharmacology, 112, pp.188~197 (2017)
- Yang C, "Mechanistic target of rapamycin-independent antidepressant effects of(R)-Ketamine in a social defeat stress model", Biol Psychiatry, 83, pp.18~28 (2018)
- Yang C, "R-ketamine : a rapid-onset and sustained antidepressant without psychotomimetic side effects", Transl Psychiatry, 5, pp.e632~ (2015)
- Riga D, "Social defeat-induced anhedonia : effects on operant sucrose-seeking behavior", Front Behav Neurosci, 9, pp.195~ (2015)
- Yang C, "Bifidobacterium in the gut microbiota confer resilience to chronic social defeat stress in mice", Sci Rep, 7, pp.45942~ (2017)
- Yang C, "(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite(2R, 6R)-hydroxynorketamine", Biol Psychiatry, 82, pp.e43~e44 (2017)
- Min Ma, "Effects of Brilliant Blue G on Serum Tumor Necrosis Factor-α Levels and Depression-like Behavior in Mice after Lipopolysaccharide Administration", Clinical Psychopharmacology and Neuroscience, 12(1), pp.31~36 (2014), 대한정신약물학회
- Olivia May Dean, "Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial", Clinical Psychopharmacology and Neuroscience, 12(3), pp.180~188 (2014), 대한정신약물학회
- Dowlati Y, "A meta-analysis of cytokines in major depression", Biol Psychiatry, 67, pp.446~457 (2010)
- Udina M, "Cytokine-induced depression : current status and novel targets for depression therapy", CNS Neurol Disord Drug Targets, 13, pp.1066~1074 (2014)
- Kohler O, "Inflammation in depression and the potential for anti-inflammatory treatment", Curr Neuropharmacol, 14, pp.732~742 (2016)
- Lawson MA, "Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice", J Neuroinflammation, 10, pp.54~ (2013)
- Berghen N, "Malignancies and anti-TNF therapy in rheumatoid arthritis : a single-center observational cohort study", Clin Rheumatol, 34, pp.1687~1695 (2015)
- Abbott R, "Tumour necrosis factor- inhibitor therapy in chronic physical illness : A systematic review and meta-analysis of the effect on depression and anxiety", J Psychosom Res, 79, pp.175~184 (2015)
- Seden Demirci, "The Serum Levels of Resistin and Its Relationship with Other Proinflammatory Cytokines in Patients with Alzheimer’s Disease", Clinical Psychopharmacology and Neuroscience, 15(1), pp.59~63 (2017), 대한정신약물학회[DOI]
- Dellarole A, "Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling", Brain Behav Immun, 41, pp.65~81 (2014)
- Lopresti AL, "A review of peripheral biomarkers in major depression : the potential of inflammatory and oxidative stress biomarkers", Prog Neuropsychopharmacol Biol Psychiatry, 48, pp.102~111 (2014)
- Brunoni AR, "Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial", Psychopharmacology(Berl), 231, pp.1315~1323 (2014)
- Decosterd I, "Spared nerve injury : an animal model of persistent peripheral neuropathic pain", Pain, 87, pp.149~158 (2000)
- Song Z, "STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia", Brain Behav Immun, 60, pp.161~173 (2017)
- Xie ZM, "Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury : improvement by ketamine", Sci Rep, 7, pp.3124~ (2017)
- Challa SR, "Surgical animal models of neuropathic pain : pros and cons", Int J Neurosci, 125, pp.170~174 (2015)
- Schmidtko A, "Nitric oxide-mediated pain processing in the spinal cord", Handb Exp Pharmacol, 227, pp.103~117 (2015)
- Hashimoto K, "A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action", Clin Psychopharmacol Neurosci, 10, pp.59~60 (2012)
- Su-Xia Li, "Antidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure", Clinical Psychopharmacology and Neuroscience, 12(2), pp.124~127 (2014), 대한정신약물학회
- Richner M, "The spared nerve injury (SNI) model of induced mechanical allodynia in mice", J Vis Exp, (54), pp.3092~ (2011)
- Pertin M, "The spared nerve injury model of neuropathic pain", Methods Mol Biol, 851, pp.205~212 (2012)
- Walker AK, "Neuroinflammation and comorbidity of pain and depression", Pharmacol Rev, 66, pp.80~101 (2013)
- Ashrafioun L, "Frequency of prescription opioid misuse and suicidal ideation, planning, and attempts", J Psychiatr Res, 92, pp.1~7 (2017)
- Paksarian D, "Stability and change in reported age of onset of depression, back pain, and smoking over 29 years in a prospective cohort study", J Psychiatr Res, 88, pp.105~112 (2017)
- Ren Q, "Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress", Proc Natl Acad Sci U S A, 113, pp.E1944~ (2016)[DOI]
- Mei Han, "Increased Levels of C1q in the Prefrontal Cortex of Adult Offspring after Maternal Immune Activation: Prevention by 7,8-Dihydroxyflavone", Clinical Psychopharmacology and Neuroscience, 15(1), pp.64~67 (2017), 대한정신약물학회[DOI]
- Abelaira HM, "Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex", J Psychiatr Res, 87, pp.81~87 (2017)
- Guida F, "Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice", Mol Brain, 8, pp.47~ (2015)
- Bräscher AK, "Different brain circuitries mediating controllable and uncontrollable pain", J Neurosci, 36, pp.5013~5025 (2016)
- Liu Z, "Prefrontal cortex to accumbens projections in sleep regulation of reward", J Neurosci, 36, pp.7897~7910 (2016)
- Petykó Z, "Responses of rat medial prefrontal cortical neurons to Pavlovian conditioned stimuli and to delivery of appetitive reward", Behav Brain Res, 287, pp.109~119 (2015)
- Ferenczi EA, "Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior", Science, 351, pp.aac9698~ (2016)
- Sekio M, "Lipopolysaccharide-induced depressive-like behavior is associated with -adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area", Int J Neuropsychopharmacol, 18, pp.pyu005~ (2014)
- Yang C, "Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable electric stress", Acta Neuropsychiatr, 27, pp.312~316 (2015)
- D’Mello C, "Immune-to-brain communication pathways in inflammation-associated sickness and depression", Curr Top Behav Neurosci, 31, pp.73~94 (2017)
- Guo D, "Spinal presynaptic inhibition in pain control", Neuroscience, 283, pp.95~106 (2014)
- Gjesdal K, "Experiences with spinal cord stimulator in patients with chronic neuropathic back pain", Pain Manag Nurs, 15, pp.e13~e24 (2014)
- Baranidharan G, "Spinal cord stimulation for visceral pain--a novel approach", Neuromodulation, 17, pp.753~758 (2014)
- Siddall PJ, "Spinal cord injury-induced pain : mechanisms and treatments", Pain Manag, 5, pp.493~507 (2015)
- Hashimoto K, "The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression", Clin Psychopharmacol Neurosci, 12, pp.72~73 (2014)
- Dang YH, "Targeting of NMDA receptors in the treatment of major depression", Curr Pharm Des, 20, pp.5151~5159 (2014)
- Yang C, "Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus", Exp Ther Med, 5, pp.1093~1096 (2013)
- Gajraj NM, "COX-2 inhibitors celecoxib and parecoxib : valuable options for postoperative pain management", Curr Top Med Chem, 7, pp.235~249 (2007)
